GH Research (NASDAQ:GHRS) Sees Unusually-High Trading Volume – Here’s What Happened

GH Research PLC (NASDAQ:GHRS) shares saw an uptick in trading volume on Wednesday . 304,799 shares traded hands during trading, an increase of 92% from the previous session’s volume of 158,809 shares.The stock last traded at $9.85 and had previously closed at $9.39.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Canaccord Genuity Group dropped their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Royal Bank of Canada initiated coverage on shares of GH Research in a report on Friday. They issued an “outperform” rating and a $31.00 target price on the stock. Stifel Nicolaus raised their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Monday, January 27th. Finally, Cantor Fitzgerald assumed coverage on GH Research in a research report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $30.67.

GH Research Stock Down 0.5 %

The firm has a market capitalization of $546.29 million, a PE ratio of -13.29 and a beta of 0.94. The firm’s 50-day moving average price is $10.73 and its two-hundred day moving average price is $9.20.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. Equities research analysts forecast that GH Research PLC will post -0.8 EPS for the current year.

Institutional Investors Weigh In On GH Research

Several hedge funds have recently bought and sold shares of GHRS. RA Capital Management L.P. grew its stake in GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock valued at $44,734,000 after acquiring an additional 85,000 shares in the last quarter. Millennium Management LLC purchased a new position in GH Research during the fourth quarter valued at approximately $145,000. Two Sigma Investments LP acquired a new position in GH Research in the 4th quarter valued at approximately $117,000. BNP Paribas Financial Markets acquired a new position in GH Research in the 4th quarter valued at approximately $44,000. Finally, Northern Trust Corp lifted its position in GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock worth $286,000 after buying an additional 8,641 shares in the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).